Life Extension Magazine January 2005
Heart and Mind
By William Davis, MD, FACC
How to Lose Weight Faster
Metabolic syndrome is, in the great majority of cases, a disease of the overweight and obese. If metabolic syndrome leads to depression and other negative emotions that further escalate the risk of heart disease, that is all the more reason to attack metabolic syndrome. Not surprisingly, the most direct, effective way to do so is to lose weight.47 Weight loss might then be a useful path to reducing the risk of both depression and heart disease. Unfortunately, that is easier said than done.
Carbohydrate-restricted programs, popularized by the Atkins and South Beach diets, are helpful weight-loss tools, though the high-saturated-fat, low-fiber approach of the Atkins’ “induction phase” makes it unhealthy for a period any longer than several weeks. In the author’s experience, people with metabolic syndrome respond in an exaggerated manner to these diets, losing weight rapidly. Losses of 10-20 pounds in the first month are not uncommon.
Along with diet, several nutritional supplements can supercharge weight-loss efforts and thereby improve many features of metabolic syndrome. They include:
White bean extract. This supplement blocks intestinal carbohydrate absorption by 66%. Taking 1500 mg twice a day with meals can lead to 3-7 pounds of weight loss in the first month of use.48 Like its prescription counterpart (acarbose), it can cause excess gas, though usually modest. Do not succumb to the temptation to indulge in carbohydrates, since the blocking effect is only partial. You can overcome the effect quite easily, for instance, with a 50-gram carbohydrate load of just two granola bars.
Calcium pyruvate. Doses of 2500 mg twice a day act as a weight-loss accelerator that is safe and ephedra-free. Calcium pyruvate also has the interesting property of “exercise enhancement,” making exercise easier and less taxing, and encouraging exercise that is longer and harder with a smoother recovery.49
Chromium. This trace mineral provides an insulin-sensitizing benefit along with a modest effect of promoting weight loss (see “Chromium: An Element Essential to Health,” Life Extension, August 2004). The dose ranges from 600 to 1000 mcg per day and is best used consistently over a period of several months. Work with your doctor to monitor your blood sugar if you have established diabetes or take medication to lower your blood sugar before you begin taking chromium.
Testosterone. Contrary to popular belief, testosterone supplementation in men is more useful in improving mood than in stoking libido.50 Feelings of sadness, fatigue, anger, and even severe depression may be associated with declining blood levels of testosterone in men in their forties and beyond. Testosterone can often result in dramatic improvement in these symptoms (see “A New, Independent Risk Factor for Heart Disease,” Life Extension, August 2004). Testosterone not only improves the psychological side of the equation, but also can improve many characteristics of metabolic syndrome through its weight-loss-promoting effects.51
Carnitine is a supplement that may be equal to testosterone in its ability to improve sexual function, boost low moods, increase energy, and promote weight loss through its effect on fat and glucose metabolism. A dose of 2000 mg per day of acetyl-L-carnitine has been found effective in most studies.52
DHEA is an adrenal hormone whose beneficial effects include its considerable ability to elevate mood, particularly in men and women with lower blood levels of DHEA-sulfate. Among the most persuasive reports is a 1999 study conducted at the National Institute of Mental Health in which 90 mg per day of DHEA significantly improved symptoms such as anhedonia (loss of interest), loss of energy, lack of motivation, emotional “numbness,” sadness, inability to cope, and worry in men and women aged 45-63.53 DHEA also improves some features of metabolic syndrome by increasing sensitivity to insulin, decreasing constriction of the body’s arteries (endothelial function), and reducing plasminogen activator inhibitor-1, a potent blood-clot-promoting protein.54,55 The most common dose is 25 mg for women aged 45 and older, and 25-50 mg for men aged 40 and older.
PGX™ is a highly viscous fiber blend of glucomannan, xanthan, and alginate that limits sugar absorption and the subsequent after-meal insulin spike. This sugar-limiting effect can occur when taking a relatively low dose of 1-3 grams before each meal. A related benefit is a modest reduction in total cholesterol and LDL. (See “Novel Fiber Limits Sugar Absorption,” Life Extension, September 2004.)
Exercise is another therapeutic tool that simultaneously addresses both metabolic syndrome and risk for heart disease. Exercise is an effective strategy to lose weight, improve insulin sensitivity, and lower levels of stress hormones. Aerobic exercise has the added capacity to improve mood. In fact, 16 weeks of exercise can be as effective as prescription antidepressant medication for depression.56,57
Depression and other negative emotions interact with coronary heart disease risk through a complex web of metabolic pathways. The clinical data are quite clear: depression, anxiety, anger, and other chronic, negative emotions substantially increase the risk of heart disease. They also contribute to development of metabolic syndrome, a potent risk factor for heart disease and diabetes.
Several nutritional supplements can be powerful additions to a program for improving mood and preventing heart disease. Fish oil stands out as the “missing link,” with research demonstrating impressive evidence of its benefits in both improving mood and reducing the risk of heart disease. Homocysteine is another potential link. Data suggest that the use of B vitamins, particularly folic acid, to reduce homocysteine translates into impressive improvement in mood and reduction of cardiovascular events.
Metabolic syndrome is now rampant across the US. This constellation of physiological disruptions triggered by weight gain can generate negative emotions as well as increased risk of heart disease. Weight loss is the most direct way to address metabolic syndrome and thereby reduce or eliminate its ill effects on health.
1. Ferketich AK, Schwartzbaum JA, Frid DJ, Moeschberger ML. Depression as an antecedent to heart disease among women and men in the NHANES I study. Arch Intern Med. 2000 May 8;160(9):1261-68.
2. Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Eaton WW. Depression, psy- chotropic medication, and risk of myocardial infarction: prospective data from the Baltimore ECA follow-up. Circulation. 1996 Dec 15;96(12):3123-9.
3. Todaro JF, Shen BJ, Niaura R, Spiro A, Ward KD. Effect of negative emotions on frequency of coronary heart disease (The Normative Aging Study). Am J Cardiol. 2003 Oct 15;92(8):901-6.
4. Suarez EC, Krishman RR, Lewis JG. The relation of severity of depressive symptoms to monocyte-associated proinflammatory cytokines and chemokines in apparently healthy men. Psychosom Med. 2003 May;65(3):362-8.
5. Musselman DL, Miller AH, Porter MR, et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression. Am J Psychiatry. 2001 Aug;158(8):1252-7.
6. Corti R, Hutter R, Badimon JJ, Fuster V. Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. J Thromb Thrombolysis. 2004 Feb;17(1):35-44.
7. Ridker PM. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J. 2004 Jul;148(1 Suppl):S19-26.
8. Roose SP, Glassman AH, Seidman, SN. Relationship between depression and other medical illnesses. JAMA. 2001 Oct 10;286(14):1687-90.
9. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease. Arch Gen Psychiatry. 1998 Jul;55(7):580-92.
10. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002 Jan 16;287(3):356-9.
11. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001 Apr;24(4):683-9.
12. Stewart TD, Atlas SA. Syndrome X, depression, and chaos: relevance to medical practice. Conn Med. 2000 Jun;64(6):343-5.
13. Carney RM, Berkman LF, Blumenthal JA, et al. Heart rate variability and depression in patients with a recent acute myocardial infarction. Psychosom Med. 2001;63:102.
14. Uauy R, Valenzuela A. Marine oils: the health benefits of n-3 fatty acids. Nutrition. 2000 Jul;16(7-8):680-4.
15. Severus WE. Littman AB, Stoll AL. Omega-3 fatty acids, homocysteine, and the increased risk of cardiovascular mortality in major depressive disorder. Harv Rev Psychiatry. 2001 Nov;9(6):280-93.
16. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002 Oct 23;288(16):2015-22.
17. RefsuM H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Ann Rev Med. 1998;49:31-62.
18. Morris MS, Fava M, Jacques PF, Selhub J Rosenbert IH. Depression and folate status in the US population. Psychother Psychosom. 2003 Mar;72(2):80-7.
19. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH. Homocysteine, folate methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry. 2000 Aug;69(2):228-32.
20. Fava M, Borus JS, Alpert JE, Nierenberg AA, Rosenbaum JF, Bottiglieri T. Folate, vitamin B12, and homocysteine in major depressive disorder. Am J Psychiatry. 1997 Mar;154(3):426-8.
21. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomized, placebo controlled trial. J Affect Disord. 2000 Nov;60(2):121-30.
22. Passeri M, Cucinotta D, Abate G, et al. Oral 5’-methyltetrahydrofolic acid in senile organic mental disorders with depression: Results of a double-blind multi-center study. Aging. 1993 Feb;5(1):63-71.
23. Godfrey PS, Toone BK, Carney MW, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 1990 Aug 18;336(8712):392-5.
24. Horrocks LA, Yeo YK. Health benefits of docosahexaenoic acid (DHA). Pharmacol Res. 1999 Sep;40(3):211-25.
25. Edwards R, Peet M, Shay J, Horrobin D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Discord. 1998 Mar;48(2-3):149-55.
26. Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry. 1998 Mar 1;43(5):315-9.
27. Tiemeier H, Van Tuijl HR, Hofman A, Kiliaan AJ, Breteler MM. Plasma fatty acid composition and depression are associated in the elderly: the Rotterdam Study. Am J Clin Nutr. 2003 Jul;78(1):40-6.
28. Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY. Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res. 1999 Mar 22;85(3):275-91.
29. Hibbeln JR. Fish consumption and major depression. Lancet. 1998 Apr 18;351(9110):1213.
30. Bates CE. Racially determined abnormal essential fatty acid and prostaglandin metabolism and food allergies linked to autoimmune, inflammatory, and psychiatric disorders among coastal British Columbia Indians. Med Hypotheses. 1988 Feb;25(2):103-9.
31. Hibbeln JR. Seafood consumption, the DHA content of mothers’ milk and prevalence rates of postpartum depression: a cross- national, ecological analysis. J Affect Dsord. 2002 May;69(1-3):15-29.
32. Williams PT, Krauss RM. Low-fat diets, lipoprotein subclasses, and heart disease risk. Am J Clin Nutr. 1999 Dec;70(6):949-50.
33. Marangell LB, Martinez JM, Zboyan HA, Kertz B, Kim HF, Puryear L. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treat- ment of major depression. Am J Psychiatry. 2003 May;160(5):996-8.
34. Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo- controlled trial . Eur Neuropsychopharmacol. 2003 Aug;13(4):267-71.
35. Stoll AL, Severus WE, Freeman MP, et al. Omega-3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-contolled trial. Arch Gen Psychiatry. 1999 May;56(5):407-12.
36. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry. 2002 Mar;159(3):477-9.
37. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry. 2002 Oct;59(10):913-9.
38. Singh RB, Niaz MA, Sharma JP, Kumar R, Rastogi V, Moshiri M. Randomized, double- blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival-4. Cardiovasc Drugs Ther. 1997 Jul;11(3):485-91.
39. Morris MS. Folate, homocysteine, and neurological function. Nutr Clin Care. 2002 May;5(3):124-32.
40. Hackam DG, Peterson JD, Spence JD. What level of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on pro- gression of carotid atherosclerosis in patients with homocst(e)ine levels above and below 14 micromol/l. Am J Hypertens. 2000 Jan;13(1 Pt1):105-10.
41. de Jong SC, Stehouwer CD, van den Berg M, Geurts TW, Bouter LM, Rauwerda JA. Normohomocysteinaemia and vitamin-treat ed hyperhomocysteinaemia are associated with similar risks of cardiovascular events in patients with premature peripheral arterial occlusive disease. A prospective cohort study. J Internal Med. 1999 Jul;246(1):87-96.
42. Vermeulen EG, Stehouwer CD, Twisk JW, et al. Effect of homocysteine-lowering treat- ment with folic acid plus vitamin B6 on pro- gression of subclinical atherosclerosis: a randomized, placebo-controlled trial. Lancet. 2000 Feb 12;355(9203):517-22.
43. Bottiglieri T. S-adenosyl-L-methionine (SAMe): from the bench to the bedside— molecular basis of a pleiotrophic molecule. Am J Clin Nutr. 2002 Nov;76(5):1151S-7S.
44. Papakostas GI, Alpert JE, Fava M. S-adenosyl-methionine in depression: a comprehensive review of the literature. Curr Psychiatry Rep. 2003 Dec;5(6):460-6.
45. McElroy SL, Kotwal R, Malhotra S, Nelson EB, Keck PE, Nemeroff CB. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry. 2004 May;65(5):634-51.
46. Raikkonen K, Matthews KA, Kuller LH. The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence? Metabolism. 2002 Dec;51(12):1573-7.
47. Reilly MP, Rader DJ. The Metabolic Syndrome: More than the sum of its parts? Circulation. 2003 Sep 30;108(13):1546-51.
48. Udani J, Hardy M, Madsen DC. Blocking carbohydrate absorption and weight loss: a clinical trial using Phase 2 brand proprietary fractionated white bean extract. Altern Med Rev. 2004 Mar;9(1):63-9.
49. Kalman D, Colker CM, Wilets I, Roufs JB, Antonio J. The effects of pyruvate supplementation on body composition in over- weight individuals. Nutrition. 1999 May;15(5):337-40.
50. Carnahan RM, Perry PJ. Depression in aging men: the role of testosterone. Drugs Aging. 2004;21(6):361-76.
51. Niskanen L, Laaksonen DE, Punnonen K, Mustajoki P, Kaukua J, Rissanen A. Changes in sex hormone-binding globulin and testos- terone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab. 2004 May;6(3):208-15.
52. Cavallini G, Caracciolo S, Vitali G, Modenini F, Biagiotti G. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology. 2004 Apr;63(4):641-6.
53. Bloch M, Schmidt PJ, Danaceau MA, Adams LF, Rubinow DR. Dehydroepiandrosterone treatment of midlife dysthymia. Biol Psychiatry. 1999 Jun 15;45(12):1531-2.
54. Lasco A, Frisina N, Morabito N, et al. Metabolic effects of dehydroepiandrosterone replacement therapy in post- menopausal women. Eur J Endnocrinol. 2001 Oct;145(4):457-61.
55. Kawano H, Yasue H, Kitagawa A, Hirai N, Yoshida T, Soejima H, et al. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab. 2003 Jul;88(7);3190-5.
56. Lett HS, Blumenthal JA, Babyak MA, et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosomatic Med. 2004 May;66(3):305-15.
57. Carroll S, Dudfield M. What is the relationship between exercise and metabolic abnormalities? A review of the metabolic syndrome. Sports Med. 2004;34:371-418.